Legal & General Group Plc Boosts Stake in Zoetis Inc. $ZTS

by · The Cerbat Gem

Legal & General Group Plc grew its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,484,969 shares of the company’s stock after buying an additional 210,769 shares during the quarter. Legal & General Group Plc owned 0.79% of Zoetis worth $543,481,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of ZTS. Vanguard Group Inc. lifted its holdings in Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after acquiring an additional 330,823 shares during the period. Geode Capital Management LLC raised its stake in shares of Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares during the period. Polen Capital Management LLC raised its stake in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp boosted its holdings in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after buying an additional 78,508 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ZTS. BTIG Research lowered their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. UBS Group decreased their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. KeyCorp assumed coverage on shares of Zoetis in a research report on Thursday. They set a “sector weight” rating for the company. Finally, Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average price target of $178.89.

View Our Latest Research Report on ZTS

Zoetis Trading Up 5.3%

Shares of ZTS opened at $122.06 on Friday. The business’s 50-day moving average price is $137.75 and its 200-day moving average price is $150.17. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $181.85. The stock has a market cap of $53.79 billion, a PE ratio of 21.01, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up .5% compared to the same quarter last year. During the same period last year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

See Also